Robin Siefker
Psychiatric/Mental Health · Marion, OHNPI 1730379272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 732 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 732 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$990
- Otsuka America Pharmaceutical, Inc.$941
- Vanda Pharmaceuticals Inc.$874
- plus $5K from 23 others
What the payments were for
- Food & beverage$12,02799%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $1,541 |
| AbbVie | 130 | $1,393 |
| Neurocrine Biosciences, Inc. | 46 | $1,201 |
| Alkermes, Inc. | 73 | $990 |
| Otsuka America Pharmaceutical, Inc. | 52 | $941 |
| Vanda Pharmaceuticals Inc. | 36 | $874 |
| Lundbeck LLC | 46 | $774 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $751 |
| Teva Pharmaceuticals USA, Inc. | 60 | $689 |
| Axsome Therapeutics, Inc. | 25 | $567 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $486 |
| Indivior Inc. | 18 | $336 |
| Avanir Pharmaceuticals, Inc. | 16 | $299 |
| Sunovion Pharmaceuticals Inc. | 19 | $247 |
| Corium, LLC | 12 | $210 |
| Supernus Pharmaceuticals, Inc. | 11 | $190 |
| Noven Therapeutics, LLC | 12 | $165 |
| Tris Pharma Inc | 5 | $91 |
| Harmony Biosciences LLC | 3 | $68 |
| Braeburn Inc. | 4 | $65 |
| Biogen | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Acadia Pharmaceuticals Inc | 3 | $41 |
| Merck | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Noven Pharmaceuticals, Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Orexo US, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$248
- SPRAVATO$135
- ABILIFY ASIMTUFII$125
- Auvelity$113
- NUEDEXTA$107
How this compares
$12,140 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 148 | $176,027 |
| VraylarCariprazine Hcl | 114 | $170,247 |
| RexultiBrexpiprazole | 45 | $68,113 |
| Invega SustennaPaliperidone Palmitate | 22 | $61,546 |
| TrintellixVortioxetine Hydrobromide | 48 | $24,866 |
| BrixadiBuprenorphine | 11 | $18,727 |
| BelsomraSuvorexant | 32 | $14,089 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $12,934 |
| ValiumDiazepam | 12 | $10,929 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 48 | $9,261 |
| Paliperidone ErPaliperidone | 31 | $7,752 |
| SeroquelQuetiapine Fumarate | 11 | $5,298 |
| Aripiprazole | 82 | $5,216 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,366 |
| Lurasidone Hcl | 24 | $3,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $1,541 | $237,573170 claims |
| AbbVieVraylar | $1,393 | $170,247114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $941 | $68,11345 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $486 | $29,23259 claims |
| Braeburn Inc.Brixadi | $65 | $18,72711 claims |
| MerckBelsomra | $26 | $14,08932 claims |
| Axsome Therapeutics, Inc.Auvelity | $567 | $12,93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Marion
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.